When to Act: Red Flags for CA LEMS in Small Cell Lung Cancer and the NCCN Testing Threshold

Dr. Primdahl describes the diagnostic delays and misattributions that characterize the CA LEMS journey in patients with SCLC. The most common sources of delay are insufficient oncologist awareness, neurophobia, and limited neurology access. Her practical advice for community oncologists without fast neurology access is to initiate serum VGCC antibody testing independently, which is a straightforward send-out test, while simultaneously pursuing a neurology referral. A positive result typically accelerates specialist access.

Dr. Sen describes the testing decision: rather than a checklist requiring every classical feature, VGCC antibody testing should function as a context-specific threshold. The single most actionable trigger is proximal muscle weakness disproportionate to disease burden, specifically, a patient who is radiographically responding but progressively weakening. Hyporeflexia, autonomic symptoms such as dry mouth, or functional decline that doesn't track with cancer behavior alongside proximal weakness are each sufficient to order VGCC testing and refer to neurology simultaneously.

The 2025 NCCN SCLC guidelines now explicitly name CA LEMS symptom recognition and recommend VGCC antibody testing under the signs and symptoms section, elevating this from clinician-dependent awareness to guideline-directed care. Testing and neurology referral can and should occur in parallel to avoid sequential delays.

Dr. Shields reinforces her practical bedside screening tool: asking patients to rise from a chair without using their arms. Difficulty doing so is her gold standard prompt for deeper investigation.